Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hypersensitivity Reaction

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 190 articles:
HTML format



Single Articles


    February 2024
  1. KOBYLETZKI LBV, Svensson A
    Long term outcome measures of atopic dermatitis gain importance: a validation study filling a research gap.
    Br J Dermatol. 2024 Feb 5:ljae049. doi: 10.1093.
    PubMed    


    January 2024
  2. DAINTY KN, Thibau IJC, Amog K, Drucker AM, et al
    Towards a patient-centered definition for atopic dermatitis flare: A qualitative study among adults with atopic dermatitis.
    Br J Dermatol. 2024 Jan 30:ljae037. doi: 10.1093.
    PubMed     Abstract available



  3. Comparing systemic treatments for eczema.
    Br J Dermatol. 2024;190:e16.
    PubMed    



  4. A study using machine learning to help identify subgroups of adults with atopic dermatitis.
    Br J Dermatol. 2024;190:e19.
    PubMed    



  5. A decreasing trend of atopic dermatitis among children in Sweden.
    Br J Dermatol. 2024;190:e17.
    PubMed    


  6. SOEGIHARTO R, Westmeijer M, Boekema-Bakker N, Groenewegen IAM, et al
    Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands.
    Br J Dermatol. 2024;190:287-289.
    PubMed    


  7. FUNCH AB, Glindvad Ahlstrom M, Johansen JD, Geisler C, et al
    Neutrophil Infiltration in Allergic Contact Dermatitis to Nickel.
    Br J Dermatol. 2024 Jan 4:ljad499. doi: 10.1093.
    PubMed    


  8. YOO LJH, Stefanovic N, Watchorn RE
    Atopic Dermatitis and Autism: Tactile Hypersensitivity Impeding on Topical Therapy Use.
    Br J Dermatol. 2024 Jan 4:ljae005. doi: 10.1093.
    PubMed    


  9. SMITH KA, Hiyoshi A, Vingeliene S, von Kobyletzki L, et al
    Atopic dermatitis and cognitive function: a sibling comparison study among males in Sweden.
    Br J Dermatol. 2024 Jan 3:ljae004. doi: 10.1093.
    PubMed    


    December 2023
  10. JOHNSON C, Smith P, Haran K, Kranyak A, et al
    Comment on 'Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study'.
    Br J Dermatol. 2023 Dec 27:ljad529. doi: 10.1093.
    PubMed    



  11. Nemolizumab reduces itch and improves other signs of atopic dermatitis in children aged 6-12 years.
    Br J Dermatol. 2023;190:e2.
    PubMed    



  12. Greater understanding about differences in the long-term course of eczema and their risk factors in children.
    Br J Dermatol. 2023;190:e5.
    PubMed    



  13. A study about how many people around the world have atopic dermatitis.
    Br J Dermatol. 2023;190:e6.
    PubMed    



  14. The role of enhancers in eczema and psoriasis.
    Br J Dermatol. 2023;190:e1.
    PubMed    


  15. TIERNEY E, Evans P, Broderick V, Wynn R, et al
    Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease.
    Br J Dermatol. 2023 Dec 20:ljad526. doi: 10.1093.
    PubMed    


  16. FORKEL S, Schubert S, Corvin L, Heine G, et al
    Contact allergies to dental materials in patients.
    Br J Dermatol. 2023 Dec 20:ljad525. doi: 10.1093.
    PubMed     Abstract available


  17. THOMAS KS, Howells L, Leshem YA, Simpson EL, et al
    How to use the HOME Core Outcome Set for atopic dermatitis trials - a users' guide.
    Br J Dermatol. 2023 Dec 20:ljad497. doi: 10.1093.
    PubMed     Abstract available


  18. ABDI P, Haq Z, Diaz MJ, Maibach HI, et al
    Infectious disease among adults with allergic contact dermatitis: A propensity score-matched case-control study.
    Br J Dermatol. 2023 Dec 19:ljad504. doi: 10.1093.
    PubMed    


  19. SOCKLER PG, Hooper SR, Abuabara K, Ma EZ, et al
    Atopic dermatitis, cognitive function, and psychiatric comorbidities across early childhood and adolescence in a population-based UK birth cohort.
    Br J Dermatol. 2023 Dec 7:ljad486. doi: 10.1093.
    PubMed     Abstract available


  20. WEIDINGER S, Simpson EL, Silverberg JI, Barbarot S, et al
    Burden of Atopic Dermatitis in Pediatric Patients: An International Cross-sectional Study.
    Br J Dermatol. 2023 Dec 4:ljad449. doi: 10.1093.
    PubMed     Abstract available


    November 2023
  21. YU J
    Are perinatal antibiotics responsible for atopic dermatitis? The Debate Rages On.
    Br J Dermatol. 2023 Nov 30:ljad477. doi: 10.1093.
    PubMed    


  22. KIM M, Choi Y, Lee M, Kang J, et al
    Maternal SARS-CoV-2 infection during pregnancy and subsequent risk of atopic dermatitis in offspring: a nationwide birth cohort study in South Korea.
    Br J Dermatol. 2023 Nov 30:ljad478. doi: 10.1093.
    PubMed    


  23. CAZZANIGA S, Simon D
    Decoding Atopic Dermatitis: Unveiling Phenotypes Through Data-Driven Methods.
    Br J Dermatol. 2023 Nov 17:ljad453. doi: 10.1093.
    PubMed    



  24. Correction to: Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.
    Br J Dermatol. 2023 Nov 16:ljad442. doi: 10.1093.
    PubMed    



  25. Improved sleep in adults with atopic dermatitis using the treatment dupilumab.
    Br J Dermatol. 2023;189:e106.
    PubMed    



  26. A clinical trial in children and young people with severe eczema comparing methotrexate with ciclosporin.
    Br J Dermatol. 2023;189:e105.
    PubMed    



  27. A study about the presence of Staphylococcus aureus growth at birth and at 2 months of age in children who developed atopic dermatitis in the first 2 years of life.
    Br J Dermatol. 2023;189:e107.
    PubMed    


  28. CHERREZ-OJEDA I, Thomsen SF, Gimenez-Arnau A
    Alexithymia prevalence in individuals with chronic urticaria and its association with illness severity and therapeutic profile.
    Br J Dermatol. 2023;189:766-767.
    PubMed    


  29. WAN J
    Changes in the epidemiology of atopic dermatitis: putting them into context.
    Br J Dermatol. 2023 Nov 11:ljad443. doi: 10.1093.
    PubMed    


  30. YOSIPOVITCH G, Lio PA, Rosmarin D, Serra-Baldrich E, et al
    Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
    Br J Dermatol. 2023 Nov 6:ljad435. doi: 10.1093.
    PubMed    


  31. RAGAMIN A, Schappin R, de Graaf M, Tupker RA, et al
    The effectiveness of antibacterial therapeutic clothing compared with non-antibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: A randomized controlled, observer-blind pragmatic trial (ABC trial).
    Br J Dermatol. 2023 Nov 4:ljad437. doi: 10.1093.
    PubMed     Abstract available


  32. HAIDER S, Granell R, Curtin JA, Holloway JW, et al
    Identification of eczema clusters and their association with filaggrin and atopic comorbidities: analysis of five birth cohorts.
    Br J Dermatol. 2023 Nov 3:ljad326. doi: 10.1093.
    PubMed     Abstract available


    October 2023
  33. CHIESA FUXENCH Z, Mitra N, Del Pozo D, Hoffstad O, et al
    In utero or early in life exposure to antibiotics and the risk of childhood atopic dermatitis, a population-based cohort study.
    Br J Dermatol. 2023 Oct 28:ljad428. doi: 10.1093.
    PubMed     Abstract available



  34. Lifetime burden of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Br J Dermatol. 2023;189:e92.
    PubMed    



  35. Safety and effectiveness of amlitelimab, a potential new treatment for atopic dermatitis: results of a clinical trial.
    Br J Dermatol. 2023;189:e90.
    PubMed    



  36. Greater understanding about interpreting the Recap of atopic eczema (RECAP) questionnaire.
    Br J Dermatol. 2023;189:e95.
    PubMed    


  37. OFENLOCH RF
    Filling the gap: investigating the interpretability of the Recap of atopic eczema questionnaire.
    Br J Dermatol. 2023;189:506-507.
    PubMed    


  38. INGEN-HOUSZ-ORO S
    Epidermal necrolysis: a chronic disease associated with loss-of-life expectancy and lifetime healthcare expenditure.
    Br J Dermatol. 2023;189:505-506.
    PubMed    


  39. LIU Y, Li Q, Chu C, Zhou Y, et al
    Insights into Stevens-Johnson syndrome/toxic epidermal necrolysis lifetime burden: assessing life expectancy, healthcare costs and quality of life.
    Br J Dermatol. 2023;189:648.
    PubMed    


  40. ZHANG J, Ragamin A, Romeijn GLE, Loman L, et al
    Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire.
    Br J Dermatol. 2023;189:578-587.
    PubMed     Abstract available


  41. WELFRINGER-MORIN A, Bataille P, Drummond D, Bellon N, et al
    Comparison of idiopathic and drug-induced epidermal necrolysis in children.
    Br J Dermatol. 2023;189:631-633.
    PubMed    


  42. NYMAND L, Nielsen ML, Vittrup I, Halling AS, et al
    Atopic dermatitis phenotypes based on cluster analysis of the Danish Skin Cohort.
    Br J Dermatol. 2023 Oct 18:ljad401. doi: 10.1093.
    PubMed     Abstract available


  43. DRUCKER AM, Lam M, Elsawi R, Prieto-Merino D, et al
    Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.
    Br J Dermatol. 2023 Oct 13:ljad393. doi: 10.1093.
    PubMed     Abstract available


    September 2023
  44. AF KLINTEBERG M, Winberg A, Andersson M, Ronmark E, et al
    Decreasing prevalence of atopic dermatitis among Swedish schoolchildren. Three repeated population-based surveys.
    Br J Dermatol. 2023 Sep 30:ljad370. doi: 10.1093.
    PubMed     Abstract available



  45. Correction to: TMEM232 promotes the inflammatory response in atopic dermatitis via the nuclear factor-kappaB and signal transducer and activator of transcription 3 signalling pathways.
    Br J Dermatol. 2023 Sep 23:ljad346. doi: 10.1093.
    PubMed    


  46. FLOHR C, Rosala-Hallas A, Jones AP, Beattie P, et al
    Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre, parallel group, assessor-blinded clinical trial.
    Br J Dermatol. 2023 Sep 19:ljad281. doi: 10.1093.
    PubMed     Abstract available


  47. NAKAHARA T, Fujita H, Tajima Y, Arima K, et al
    Evaluating the usefulness of the Atopic Dermatitis Control Tool for assessing disease control among individuals with atopic dermatitis in Japan.
    Br J Dermatol. 2023 Sep 15:ljad344. doi: 10.1093.
    PubMed    



  48. The risk of deep-vein blood clots in people with atopic dermatitis (eczema).
    Br J Dermatol. 2023;189:e75.
    PubMed    



  49. A review of major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors.
    Br J Dermatol. 2023;189:e69.
    PubMed    


  50. VOORBERG AN, Kamphuis E, Christoffers WA, Schuttelaar MLA, et al
    Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.
    Br J Dermatol. 2023;189:400-409.
    PubMed     Abstract available


  51. TIAN J, Zhang D, Yang Y, Huang Y, et al
    The global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study.
    Br J Dermatol. 2023 Sep 14:ljad339. doi: 10.1093.
    PubMed     Abstract available


  52. FUXENCH ZCC, Wan J, Wang S, Syed MN, et al
    Atopic Dermatitis and risk for headache disorders and migraines: a population-based cohort study in children and adults from the United Kingdom.
    Br J Dermatol. 2023 Sep 6:ljad325. doi: 10.1093.
    PubMed    


  53. LLOYD-LAVERY A
    Nemolizumab to target the itch-scratch cycle in paediatric atopic dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad319. doi: 10.1093.
    PubMed    


  54. SUI JY, Eichenfield DZ, Sun BK
    The Role of Enhancers in Psoriasis and Atopic Dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad321. doi: 10.1093.
    PubMed     Abstract available


  55. LEE EY, Drucker AM
    A detailed evaluation of dupilumab's effect on sleep in adults with atopic dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad320. doi: 10.1093.
    PubMed    


    August 2023

  56. The impact of a dose reduction of dupilumab when treating people with well-controlled atopic dermatitis.
    Br J Dermatol. 2023;189:e68.
    PubMed    


  57. ROESNER LM, Wittmann M
    Hand eczema leaves systemic traces.
    Br J Dermatol. 2023;189:e56-e59.
    PubMed    


  58. ARENTS BWM, van Zuuren EJ, Hughes O, Fedorowicz Z, et al
    The future is now: the Global Atopic Dermatitis Atlas (GADA).
    Br J Dermatol. 2023 Aug 11:ljad286. doi: 10.1093.
    PubMed    


  59. MEROLA JF, Chiou AS, During E, Costanzo A, et al
    Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase 4 randomized double-blinded placebo-controlled DUPISTAD study.
    Br J Dermatol. 2023 Aug 10:ljad284. doi: 10.1093.
    PubMed     Abstract available


    July 2023
  60. IGARASHI A, Katsunuma T, Matsumura T, Komazaki H, et al
    Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: Results from a phase III, randomised, double-blind, placebo-controlled, multicentre study.
    Br J Dermatol. 2023 Jul 31:ljad268. doi: 10.1093.
    PubMed     Abstract available


  61. RINNOV MR, Gerner T, Halling AS, Liljendahl MS, et al
    The association between S. aureus colonization on cheek skin at 2 months and subsequent atopic dermatitis in a prospective birth cohort.
    Br J Dermatol. 2023 Jul 22:ljad249. doi: 10.1093.
    PubMed     Abstract available


  62. WEIDINGER S, Bieber T, Cork MJ, Reich A, et al
    Safety and efficacy of amlitelimab, a fully human, non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomised placebo-controlled trial.
    Br J Dermatol. 2023 Jul 18:ljad240. doi: 10.1093.
    PubMed     Abstract available



  63. Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol. 2023;189:e39.
    PubMed    


  64. LAM M, Spuls PI, Leshem YA, Gerbens LAA, et al
    Reporting of Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set Instruments in randomized clinical trials for systemic treatments in Atopic Dermatitis.
    Br J Dermatol. 2023 Jul 12:ljad237. doi: 10.1093.
    PubMed    


  65. CHIU YM, Chiu HY
    Lifetime risk, life expectancy, loss-of-life expectancy, and lifetime healthcare expenditure for Stevens-Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019.
    Br J Dermatol. 2023 Jul 10:ljad234. doi: 10.1093.
    PubMed     Abstract available



  66. Better understand about circulating biomarkers and disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2023;189:e34.
    PubMed    


  67. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2023;189:53-61.
    PubMed     Abstract available


  68. WARREN RB, Basey V, Lynam A, Curtis C, et al
    The risk of venous thromboembolism in atopic dermatitis: A matched cohort analysis in UK primary care.
    Br J Dermatol. 2023 Jul 7:ljad212. doi: 10.1093.
    PubMed     Abstract available


  69. CONNOLLY A, Walsh S, Philippidou M, Salisbury J, et al
    Acute hepatic failure in trimethoprim-induced drug rash with eosinophilia and systemic symptoms (DRESS).
    Br J Dermatol. 2023;189:140-141.
    PubMed    


  70. ERTUS C, Scailteux LM, Lescoat A, Berthe P, et al
    Major adverse cardiovascular events in patients treated with oral Janus kinase inhibitors for atopic dermatitis: a systematic review and meta-analysis.
    Br J Dermatol. 2023 Jul 6:ljad229. doi: 10.1093.
    PubMed     Abstract available


  71. OLLECH A, Lefferdink R, Sheth A, Blumstein A, et al
    Systemic Immunosuppressive Therapies for Children with Refractory Atopic Dermatitis: A Large Real-Life Cohort Study.
    Br J Dermatol. 2023 Jul 5:ljad222. doi: 10.1093.
    PubMed    


  72. HONG CH, Lee CH
    A nationwide UK cohort study reveals an association between atopic dermatitis and venous thromboembolism.
    Br J Dermatol. 2023 Jul 5:ljad221. doi: 10.1093.
    PubMed    


    June 2023
  73. RUTH E, Heraghty F, Flynn N, McGlynn T, et al
    No evidence of isotretinoin sensitisation in peanut allergic children - a cross-sectional study.
    Br J Dermatol. 2023 Jun 28:ljad214. doi: 10.1093.
    PubMed    


  74. LUO M, Zhu C, Lin J, Lin L, et al
    Bidirectional Mendelian randomization analysis did not indicate a causal relationship between atopic dermatitis and COVID-19.
    Br J Dermatol. 2023 Jun 27:ljad208. doi: 10.1093.
    PubMed    


  75. OGAWA-MOMOHARA M, Muro Y, Murase C, Taki T, et al
    Allergen-specific IgG4 increase in atopic dermatitis with long-term dupilumab use.
    Br J Dermatol. 2023 Jun 27:ljad207. doi: 10.1093.
    PubMed    


  76. HAN JH, Ju HJ, Kang H, Lee JH, et al
    Autoimmune, Inflammatory, Allergic, and Neuropsychiatric Outcomes of Offspring Born to Mothers with Vitiligo: A Nationwide Population-based Birth Cohort Study of Korea.
    Br J Dermatol. 2023 Jun 19:ljad196. doi: 10.1093.
    PubMed    


    May 2023

  77. Results from 1 year of treatment with lebrikizumab for atopic dermatitis.
    Br J Dermatol. 2023;188:e43.
    PubMed    



  78. Atopic eczema: palmar patterns associated with filaggrin variants, disease severity and barrier function in a South Asian population.
    Br J Dermatol. 2023;188:e46.
    PubMed    



  79. Atopic dermatitis across the globe: differences in prevalence and access to treatments.
    Br J Dermatol. 2023;188:e42.
    PubMed    


  80. THOMAS BR, Tan XL, Van Duijvenboden S, Hogan SC, et al
    Deep palmar phenotyping in atopic eczema: patterns associated with filaggrin variants, disease severity and barrier function in a South Asian population.
    Br J Dermatol. 2023;188:785-792.
    PubMed     Abstract available


  81. HIJNEN D, Olydam J
    Prediction of response to dupilumab treatment.
    Br J Dermatol. 2023;188:e41.
    PubMed    



  82. Correction to: 319 Effects of omega-3 fatty acid supplementation on atopic dermatitis.
    Br J Dermatol. 2023 May 22:ljad154. doi: 10.1093.
    PubMed    


  83. SPEKHORST LS, Boesjes CM, Loman L, Zuithoff NPA, et al
    Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry.
    Br J Dermatol. 2023 May 13:ljad159. doi: 10.1093.
    PubMed     Abstract available


    April 2023
  84. FLOHR C, Irvine AD, Cork MJ, Simpson EL, et al
    Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol. 2023 Apr 30:ljad124. doi: 10.1093.
    PubMed    


  85. ARENTS BWM
    Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2023 Apr 24:ljad068. doi: 10.1093.
    PubMed    



  86. Serum biomarker analysis to identify subtypes of atopic dermatitis in China and to help with predicting the effectiveness of treatment with dupilumab.
    Br J Dermatol. 2023;188:e37.
    PubMed    


  87. BEN ABDALLAH H, Johansen C
    Transmembrane protein 232 (TMEM232) regulates inflammation in experimental models of atopic dermatitis.
    Br J Dermatol. 2023 Apr 17:ljad127. doi: 10.1093.
    PubMed    


  88. QUAADE AS, Wang X, Solberg JBK, Ulrich NH, et al
    Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2023 Apr 13:ljad110. doi: 10.1093.
    PubMed     Abstract available


  89. VITTRUP I
    Malignancy risk in atopic dermatitis: heterogenous effects and perspectives.
    Br J Dermatol. 2023 Apr 11:ljad119. doi: 10.1093.
    PubMed    


    March 2023
  90. TORRELO A, Rewerska B, Galimberti M, Paller A, et al
    Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, place
    Br J Dermatol. 2023 Mar 31:ljad096. doi: 10.1093.
    PubMed     Abstract available


  91. BLAUVELT A, Thyssen JP, Guttman-Yassky E, Bieber T, et al
    Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
    Br J Dermatol. 2023 Mar 30:ljad022. doi: 10.1093.
    PubMed     Abstract available



  92. Factors associated with mental illness in adults with atopic eczema or psoriasis.
    Br J Dermatol. 2023;188:e27.
    PubMed    



  93. Quality of life of Bangladeshi children and young adults with atopic eczema and their families in East London.
    Br J Dermatol. 2023;188:e33.
    PubMed    


  94. TAWFIK SS, Thomas BR, Kelsell DP, Grigg J, et al
    Dermatology Quality of Life Index scores in Bangladeshi patients with atopic eczema and their families in East London.
    Br J Dermatol. 2023;188:524-532.
    PubMed     Abstract available


  95. MAGIN P, Fisher K
    Online behavioural interventions for children and young people with atopic eczema: refining the way forward.
    Br J Dermatol. 2023;188:453.
    PubMed    


  96. VANCE TM, Li T, Cho E, Drucker AM, et al
    Prenatal antibiotic use and subsequent risk of atopic eczema.
    Br J Dermatol. 2023;188:561-563.
    PubMed    


  97. CAPOZZA K
    Lost in translation: understanding the experience of atopic eczema among non-English-speaking families.
    Br J Dermatol. 2023;188:456-457.
    PubMed    


  98. SINIKUMPU SP, Jokelainen J, Huilaja L
    The association between atopic dermatitis and acne: a retrospective Finnish nationwide registry study.
    Br J Dermatol. 2023 Mar 22:ljad086. doi: 10.1093.
    PubMed    


  99. RAGAMIN A, Tupker RA, de Graaf M, Rustemeyer T, et al
    Investigator Global Assessment for impetiginization in Atopic Dermatitis (IGA impetiginization): Development and initial reliability testing.
    Br J Dermatol. 2023 Mar 22:ljad085. doi: 10.1093.
    PubMed    


  100. PATHMARAJAH P, Corso R, Salam A, Shah G, et al
    Neutropenia in patients on dupilumab for atopic dermatitis: a case series and review of trial data.
    Br J Dermatol. 2023 Mar 17:ljad038. doi: 10.1093.
    PubMed    


  101. HAN J, Cai X, Qin S, Zhang Z, et al
    TMEM232 Promotes the Inflammatory Response in Atopic Dermatitis via NF-kappaB and STAT3 Signaling Pathways.
    Br J Dermatol. 2023 Mar 17:ljad078. doi: 10.1093.
    PubMed     Abstract available


  102. MOSAM A, Todd G
    Global epidemiology and disparities in atopic dermatitis.
    Br J Dermatol. 2023 Mar 7:ljad042. doi: 10.1093.
    PubMed     Abstract available


  103. DRUCKER AM
    Atopic dermatitis in 2023 and beyond.
    Br J Dermatol. 2023 Mar 2:ljad053. doi: 10.1093.
    PubMed    


    February 2023

  104. Atopic dermatitis and school performance in children and young adults.
    Br J Dermatol. 2023;188:e21.
    PubMed    


  105. SUN X, Sheng A, Xu AE
    Successful treatment of vitiligo with crisaborole ointment: a report of two cases.
    Br J Dermatol. 2023;188:436-437.
    PubMed    


  106. VON KOBYLETZKI L
    Which patients with atopic eczema and psoriasis develop depression, anxiety, and severe mental illness: is the evidence clear?
    Br J Dermatol. 2023 Feb 15:ljad009. doi: 10.1093.
    PubMed    



  107. Small particles of cobalt cause eczema in people with allergies.
    Br J Dermatol. 2023;188:e20.
    PubMed    



  108. Patients successfully treated with baricitinib for atopic dermatitis: what happens if they lower their dose or stop treatment?
    Br J Dermatol. 2023;188:e14.
    PubMed    


  109. REICH K, Simpson E, Wollenberg A, Bissonnette R, et al
    Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
    Br J Dermatol. 2023;188:208-217.
    PubMed     Abstract available


  110. GILL K, Xu J, Kozera E, Stewart T, et al
    Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility.
    Br J Dermatol. 2023;188:294-295.
    PubMed    


  111. SYMANZIK C, John SM
    Occupational exposure to cobalt nanoparticles: potential implications on risk assessment and preventive measures.
    Br J Dermatol. 2023;188:161-162.
    PubMed    


  112. WU Y, Gu C, Wang S, Yin H, et al
    Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab.
    Br J Dermatol. 2023 Feb 9:ljad032. doi: 10.1093.
    PubMed     Abstract available


    January 2023
  113. MCSWEENEY SM, Bintcliffe K, Fassihi H, Sarkany R, et al
    Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria.
    Br J Dermatol. 2023 Jan 27:ljad012. doi: 10.1093.
    PubMed    


  114. SIMPSON RC
    Safety of tralokinumab in atopic dermatitis.
    Br J Dermatol. 2023 Jan 26:ljad007. doi: 10.1093.
    PubMed    


  115. KOGAME T, Yonekura S, Lovato P, Hirata M, et al
    Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis.
    Br J Dermatol. 2023;188:146-148.
    PubMed    


  116. ZHANG J, Schuttelaar MLA
    Water and adult eczema: the hard truth?
    Br J Dermatol. 2023;188:e1.
    PubMed    


  117. VINCENT R, Ormerod E, Gollins CE, Rai N, et al
    Semi-virtual patch testing: the future?
    Br J Dermatol. 2023;188:137-139.
    PubMed    


  118. ARDERN-JONES MR, Buchanan EE, Njungu S, O'Driscoll D, et al
    Successful Dose Reduction of Dupilumab in Atopic Dermatitis.
    Br J Dermatol. 2023 Jan 20:ljad011. doi: 10.1093.
    PubMed    


  119. YEW YW, Apfelbacher CJ
    Validation of novel diagnostic criteria for atopic dermatitis in an adult and elderly Chinese population.
    Br J Dermatol. 2023 Jan 5:ljac143. doi: 10.1093.
    PubMed    


    December 2022
  120. ADESANYA EI, Matthewman J, Schonmann Y, Hayes JF, et al
    Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis.
    Br J Dermatol. 2022 Dec 19:ljac132. doi: 10.1093.
    PubMed     Abstract available


  121. YUE W, Cheng D, Sun Z, Shen Y, et al
    Validation of diagnostic criteria for atopic dermatitis and proposal of novel diagnostic criteria for adult and elderly Chinese populations: a multicentre, prospective, clinical setting-based study.
    Br J Dermatol. 2022 Dec 12:ljac097. doi: 10.1093.
    PubMed     Abstract available


  122. FLOHR C
    How we treat atopic dermatitis now and how that will change over the next 5 years.
    Br J Dermatol. 2022 Dec 7:ljac116. doi: 10.1093.
    PubMed     Abstract available


  123. GABES M, Ragamin A, Baker A, Kann G, et al
    Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study.
    Br J Dermatol. 2022;187:919-926.
    PubMed     Abstract available


    November 2022
  124. HU C, Jansen PW
    Do adolescents with atopic dermatitis have lower cognitive function and school performance than their peers without atopic dermatitis?
    Br J Dermatol. 2022 Nov 29:ljac105. doi: 10.1093.
    PubMed    


  125. ABUABARA K, Langan SM
    Atopic dermatitis across the life course.
    Br J Dermatol. 2022 Nov 18:ljac072. doi: 10.1093.
    PubMed     Abstract available


  126. TRIER AM, Kim BS
    Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies.
    Br J Dermatol. 2022 Nov 18:ljac016. doi: 10.1093.
    PubMed     Abstract available


  127. WEISSHAAR E, Bentz P, Haufe E, Heinrich L, et al
    Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany.
    Br J Dermatol. 2022 Nov 17:ljac070. doi: 10.1093.
    PubMed    


  128. CLAYTON K, Holbrook DJ, Vallejo A, Porter G, et al
    Skin programming of inflammatory responses to Staphylococcus aureus is compartmentalized according to epidermal keratinocyte differentiation status.
    Br J Dermatol. 2022 Nov 17:ljac088. doi: 10.1093.
    PubMed     Abstract available


  129. VITTRUP I, Andersen YMF, Skov L, Wu JJ, et al
    The association between atopic dermatitis, cognitive function and school performance in children and young adults.
    Br J Dermatol. 2022 Nov 3:ljac058. doi: 10.1093.
    PubMed     Abstract available


  130. ORCHARD D
    Preventing atopic eczema: vitamin D supplementation another piece of the puzzle?
    Br J Dermatol. 2022;187:630-631.
    PubMed    


  131. EL-HEIS S, D'Angelo S, Curtis EM, Healy E, et al
    Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial.
    Br J Dermatol. 2022;187:659-666.
    PubMed     Abstract available


    October 2022
  132. MIDANDER K, Werner P, Isaksson M, Wisgrill L, et al
    Cobalt nanoparticles cause allergic contact dermatitis in humans.
    Br J Dermatol. 2022 Oct 28:ljac043. doi: 10.1093.
    PubMed     Abstract available


  133. TURNER CT, Zeglinski MR, Boivin W, Zhao H, et al
    Granzyme K contributes to endothelial microvascular damage and leakage during skin inflammation.
    Br J Dermatol. 2022 Oct 23:ljac017. doi: 10.1093.
    PubMed     Abstract available


  134. CUCKA B, Biglione B, Zhou L, Phillips EJ, et al
    Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with COVID-19: a case series from a large US healthcare system.
    Br J Dermatol. 2022;187:619-622.
    PubMed    


    September 2022
  135. SIMPSON EL, Merola JF, Silverberg JI, Reich K, et al
    Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials.
    Br J Dermatol. 2022 Sep 9. doi: 10.1111/bjd.21867.
    PubMed     Abstract available


  136. KIM RW, Barta K, Begolka WS, Capozza K, et al
    The quantitative impact of atopic dermatitis on caregivers across multiple life domains.
    Br J Dermatol. 2022 Sep 3. doi: 10.1111/bjd.21855.
    PubMed    



  137. Revolutionizing Atopic Dermatitis, 9-11 April 2022.
    Br J Dermatol. 2022;187:e80-e155.
    PubMed    


    August 2022
  138. LANDIS MN, Arya M, Smith S, Draelos Z, et al
    Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomised, double-blind, vehicle-controlled, dose-ranging, and parallel-group study.
    Br J Dermatol. 2022 Aug 20. doi: 10.1111/bjd.21826.
    PubMed     Abstract available


  139. KIM RW, Barta K, Begolka WS, Capozza K, et al
    Qualitative analysis of the impact of atopic dermatitis on caregivers and the quantitative impact of atopic dermatitis on caregivers across multiple life domains.
    Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21828.
    PubMed    


  140. CHRISTIANSEN AG, Carstensen O, Sommerlund M, Clausen PA, et al
    Prevalence of skin sensitisation and dermatitis among epoxy-exposed workers in the wind turbine industry.
    Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21830.
    PubMed     Abstract available


  141. MORGAN CL, Thomas M, Stander S, Jabbar-Lopez ZK, et al
    Epidemiology of prurigo nodularis in England: a retrospective database analysis.
    Br J Dermatol. 2022;187:188-195.
    PubMed     Abstract available


    July 2022
  142. YANG N, Chen L, Shao J, Jiang F, et al
    Dupilumab with concomitant JAK inhibitor: A novel treatment strategy for atopic dermatitis with poor response to dupilumab.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21776.
    PubMed    


  143. WORM M, Thyssen JP, Schliemann S, Bauer A, et al
    The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
    Br J Dermatol. 2022;187:42-51.
    PubMed     Abstract available


    June 2022
  144. SCHNEEWEISS MC, Kirchgesner J, Wyss R, Jin Y, et al
    Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study.
    Br J Dermatol. 2022 Jun 19. doi: 10.1111/bjd.21704.
    PubMed     Abstract available


  145. BETTUZZI T, Hua C, Diaz E, Colin A, et al
    Epidermal necrolysis: characterization of different phenotypes using an unsupervised clustering analysis.
    Br J Dermatol. 2022;186:1037-1039.
    PubMed    


    May 2022
  146. CHEN CW, Wei JC
    Response to 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes'.
    Br J Dermatol. 2022;186:910-911.
    PubMed    


  147. GOLDENBERG M, Krishna SG, Milani-Nejad N, Trinidad JC, et al
    Response to: 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9(th) and 10(th) Revision codes': reply from the authors.
    Br J Dermatol. 2022;186:911.
    PubMed    


    April 2022
  148. BIEBER T, Reich K, Paul C, Tsunemi Y, et al
    Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response, Intolerance, or Contraindication to Cyclosporine: Results From a Randomized, Placebo-Control
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21630.
    PubMed     Abstract available


  149. LAQUER V, Parra V, Lacour JP, Takahashi H, et al
    IL-33 antibody failed to demonstrate benefit in a phase 2 double-blind, randomised placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21631.
    PubMed    


  150. JENDOUBI F, Shourik J, Seneschal J, Giordano-Labadie F, et al
    Longer Dupilumab Dosing Intervals in Adult Patients with Atopic Dermatitis: Experience from a French Multicentre Retrospective Cohort Study.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21628.
    PubMed    


  151. SIMPSON EL, Bissonnette R, Paller AS, King B, et al
    The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): A Clinical Outcome Measure for the Severity of Atopic Dermatitis.
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21615.
    PubMed     Abstract available



  152. Revolutionizing Atopic Dermatitis, 11-13 December 2021.
    Br J Dermatol. 2022;186:e135-e185.
    PubMed    


  153. BARBAROT S
    Targeting the itch-scratch vicious circle in atopic eczema.
    Br J Dermatol. 2022;186:608.
    PubMed    


    March 2022
  154. JACOBY TV, Otto TS, Asdourian MS, Shah N, et al
    Association of preexisting drug allergies with cutaneous immune related adverse events among patients on immune checkpoint inhibitor therapy.
    Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21243.
    PubMed    


  155. NOVAK N, Cabanillas B
    Herpesvirus, serious and opportunistic infections associated with atopic dermatitis.
    Br J Dermatol. 2022 Mar 6. doi: 10.1111/bjd.20982.
    PubMed    


  156. SABROE RA, Lawlor F, Grattan CEH, Ardern-Jones MR, et al
    British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021.
    Br J Dermatol. 2022;186:398-413.
    PubMed    


  157. GOLDENBERG M, Amigo M, Krishna SG, Milani-Nejad N, et al
    Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes.
    Br J Dermatol. 2022;186:583-585.
    PubMed    


    February 2022
  158. NGUYEN R
    Ocular conjunctivitis in biological therapies for atopic dermatitis.
    Br J Dermatol. 2022 Feb 16. doi: 10.1111/bjd.20945.
    PubMed    


  159. FUTAMURA M
    Easy assessment tool for disease severity of atopic dermatitis in clinical practice.
    Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20951.
    PubMed    


  160. MARGOLIS DJ
    Atopic dermatitis: filaggrin and skin barrier dysfunction.
    Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20946.
    PubMed    


  161. GLEESON D, Cliff S, Das M
    Eruptive keratoacanthomas associated with dupilumab therapy.
    Br J Dermatol. 2022;186:376-377.
    PubMed     Abstract available


  162. GAUDIN O, Milpied B, Papouin B, Hue S, et al
    Lupus erythematosus and epidermal necrolysis: a case series of 16 patients.
    Br J Dermatol. 2022;186:372-374.
    PubMed    


    January 2022
  163. PAKHCHANIAN H, Raiker R, Wolf M, Trotter SC, et al
    Examining the Risk of Breakthrough Infection and COVID-19 Vaccination Safety in Atopic Dermatitis Patients.
    Br J Dermatol. 2022 Jan 27. doi: 10.1111/bjd.21038.
    PubMed    


  164. PENNY CL, Quow K, Rundle CW, Al-Rohil RN, et al
    Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
    Br J Dermatol. 2022 Jan 19. doi: 10.1111/bjd.21022.
    PubMed    


  165. EBATA T
    Dose flexibility of oral Janus kinase inhibitors for long-term control of atopic dermatitis.
    Br J Dermatol. 2022 Jan 19:ljac082. doi: 10.1093.
    PubMed    


  166. YOSIPOVITCH G, Papp K, Forman S, Han G, et al
    The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21015.
    PubMed    


  167. KOZERA E, Stewart T, Gill K, De La Vega MA, et al
    Dupilumab Associated Head and Neck Dermatitis is Associated with Elevated Pre-Treatment Serum Malassezia-Specific Immunoglobulin E: A Multicenter, Prospective Cohort Study.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21019.
    PubMed    


  168. KEZIC S, McAleer MA, Jakasa I, Goorden SMI, et al
    Children with atopic dermatitis show increased activity of beta- glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to local cytokine milieu.
    Br J Dermatol. 2022 Jan 7. doi: 10.1111/bjd.20979.
    PubMed     Abstract available


  169. ARENTS BWM, Zuuren EJV, Vermeulen S, Schoones JW, et al
    Global Guidelines in Dermatology Mapping Project (GUIDEMAP) - a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)?
    Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20972.
    PubMed     Abstract available


    November 2021
  170. SINIKUMPU SP, Huilaja L
    Challenges of multidimensional atopic dermatitis.
    Br J Dermatol. 2021 Nov 24. doi: 10.1111/bjd.20874.
    PubMed    


  171. DEZOTEUX F, El Mesbahi S, Tedbirt B, Grosjean J, et al
    Immunomodulatory or/and immunosuppressive drugs should not avoid skin test for the assessment of drug allergy.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20901.
    PubMed     Abstract available


  172. MARNIQUET ME, Seneschal J, Darrigade AS, Staumont-Salle D, et al
    Reasons for Discontinuation of dupilumab in Adult Atopic Dermatitis in Clinical Practice.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20883.
    PubMed     Abstract available


  173. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Risk of herpesvirus, serious, and opportunistic infections in atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20887.
    PubMed     Abstract available


  174. CHIESA Z
    How important is it to distinguish between eczema and atopic dermatitis in infants? Implications for prognosis and epidemiological research.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20814.
    PubMed    


  175. BEN ABDALLAH H, Vestergaard C
    Atopic dermatitis, hypertension and cardiovascular disease.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20802.
    PubMed    


  176. PALLER AS, Tan JKL, Bagel J, Rossi AB, et al
    IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20872.
    PubMed     Abstract available


  177. KABASHIMA K, Matsumura T, Komazaki H, Kawashima M, et al
    Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20873.
    PubMed     Abstract available


    October 2021
  178. HOYER A, Rehbinder EM, Fardig M, Asad S, et al
    Filaggrin mutations in relation to skin barrier and atopic dermatitis in early infancy.
    Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20831.
    PubMed     Abstract available


  179. GUTERMUTH J, Pink AE, Worm M, Soldbro L, et al
    Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of cyclosporine A: a placebo-controlled, randomized, Phase 3 clinical trial (ECZTRA 7).
    Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20832.
    PubMed     Abstract available


  180. WOLLENBERG A, Beck LA, de Bruin Weller M, Simpson EL, et al
    Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.
    Br J Dermatol. 2021 Oct 12. doi: 10.1111/bjd.20810.
    PubMed     Abstract available


  181. PUELLES J, Fofana F, Rodriguez D, Silverberg JI, et al
    Psychometric Validation and Responder Definition of Sleep Disturbance Numerical Rating Scale in Moderate-To-Severe Atopic Dermatitis.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20783.
    PubMed     Abstract available


  182. BERMINGHAM WH, Ardern-Jones MR, Huissoon AP, Krishna MT, et al
    Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-CoV-2 vaccine uptake and global public health.
    Br J Dermatol. 2021;185:838-839.
    PubMed    


  183. FLORES C
    Decoding the pharmacogenetics of nonsteroidal anti-inflammatory drug hypersensitivity.
    Br J Dermatol. 2021;185:697-698.
    PubMed    


  184. STANDL M
    Addressing the causality of the association of atopic dermatitis with depression and anxiety using Mendelian randomization.
    Br J Dermatol. 2021;185:694-695.
    PubMed    


  185. JURADO-ESCOBAR R, Dona I, Perkins JR, Laguna JJ, et al
    Polymorphisms in eicosanoid-related biosynthesis enzymes associated with acute urticaria/angioedema induced by nonsteroidal anti-inflammatory drug hypersensitivity.
    Br J Dermatol. 2021;185:815-824.
    PubMed     Abstract available


  186. BAURECHT H, Welker C, Baumeister SE, Weidnger S, et al
    Relationship between atopic dermatitis, depression and anxiety: a two-sample Mendelian randomization study.
    Br J Dermatol. 2021;185:781-786.
    PubMed     Abstract available


    September 2021
  187. NAKAMURA T, Haider S, Fontanella S, Murray CS, et al
    Modelling trajectories of parentally reported and physician-confirmed atopic dermatitis in a birth cohort study.
    Br J Dermatol. 2021 Sep 26. doi: 10.1111/bjd.20767.
    PubMed     Abstract available


  188. FORSYTH JR, Russell E, McPherson T
    A retrospective case series of paediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: evaluation of practice using the British Association of Dermatology's National Guidelines for children and young people.
    Br J Dermatol. 2021 Sep 4. doi: 10.1111/bjd.20741.
    PubMed     Abstract available


    August 2021
  189. JACOBY TV, Chang MS, Thompson LL, Foreman RK, et al
    Histopathologically-confirmed lichenoid eruptions from immune checkpoint inhibitor therapy: A retrospective cohort analysis.
    Br J Dermatol. 2021 Aug 10. doi: 10.1111/bjd.20698.
    PubMed     Abstract available


    March 2021
  190. SCHONMANN Y, Mansfield KE, Mulick A, Roberts A, et al
    Inflammatory Skin Diseases and the Risk of Chronic Kidney Disease - Population-Based Case-control and Cohort analyses.
    Br J Dermatol. 2021 Mar 17. doi: 10.1111/bjd.20067.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hypersensitivity Reaction is free of charge.